Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HURA
stocks logo

HURA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent
Wall Street analysts forecast HURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HURA is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast HURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HURA is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.980
sliders
Low
8.00
Averages
10.00
High
12.00
Current: 1.980
sliders
Low
8.00
Averages
10.00
High
12.00
Maxim
Maxim
Buy
downgrade
$15 -> $8
2025-11-14
Reason
Maxim
Maxim
Price Target
$15 -> $8
2025-11-14
downgrade
Buy
Reason
Maxim lowered the firm's price target on TuHURA Biosciences to $8 from $15 and keeps a Buy rating on the shares.
Brookline
NULL
to
Buy
initiated
$9
2025-06-23
Reason
Brookline
Price Target
$9
2025-06-23
initiated
NULL
to
Buy
Reason
Brookline initiated coverage of TuHURA Biosciences with a Buy rating and $9 price target. TuHURA Biosciences is advancing innate immune agonists, checkpoint inhibitors, and antibody-drug conjugates to overcome checkpoint inhibitor resistance and to modulate tumor microenvironment, the analyst tells investors in a research note. The firm sees a favorable risk-reward as IFx-2.0 advances through the clinic, saying there is a significant unmet need for treatments to overcome CPI resistance in Merkel cell carcinoma.
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$13 → $12
2025-04-03
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$13 → $12
2025-04-03
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Initiates
$13
2025-03-03
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$13
2025-03-03
Initiates
Strong Buy
Reason
Rodman & Renshaw
Tony Butler
Strong Buy
Initiates
$11
2024-12-19
Reason
Rodman & Renshaw
Tony Butler
Price Target
$11
2024-12-19
Initiates
Strong Buy
Reason
Rodman & Renshaw initiated coverage of TuHURA Biosciences with a Buy rating and $11 price target. TuHURA is focused on developing treatments to overcome primary and acquired resistance to checkpoint inhibitors by using its proprietary technology platform, Immune FxTM, the analyst tells investors in a research note. The firm says the company's strategy leverages bacterial proteins to activate the immune system avoids common issues like the toxicity and infections often linked to using attenuated bacteria for cancer therapy.
See All Ratings

Valuation Metrics

The current forward P/E ratio for TuHURA Biosciences Inc (HURA.O) is -3.78, compared to its 5-year average forward P/E of -6.98. For a more detailed relative valuation and DCF analysis to assess TuHURA Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.98
Current PE
-3.78
Overvalued PE
-3.62
Undervalued PE
-10.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased837.5%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

HURA News & Events

Events Timeline

(ET)
2025-07-01
08:53:46
TuHURA Biosciences included in Russell 3000 and 2000 Indexes
select
2025-06-24 (ET)
2025-06-24
08:04:58
TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma
select
2025-06-23 (ET)
2025-06-23
17:03:00
TuHURA Biosciences, Kineta stockholders approve merger and related proposals
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-15NASDAQ.COM
Maxim Group Continues to Recommend Buy for TuHURA Biosciences (HURA)

  • Analyst Recommendation: Maxim Group has maintained a Buy recommendation for TuHURA Biosciences, with a projected one-year price target of $11.54/share, indicating a potential upside of 458.78% from its current price of $2.06/share.

  • Fund Sentiment: There has been a significant increase in institutional interest in TuHURA Biosciences, with 119 funds reporting positions, marking an 83.08% increase in ownership over the last quarter.

  • Shareholder Activity: Notable shareholders include Vanguard Total Stock Market Index Fund, which increased its holdings by 15.22%, and Geode Capital Management, which also increased its shares but reduced its portfolio allocation by 42.57%.

  • Fintel Overview: Fintel provides comprehensive investing research, including fundamentals, analyst reports, and fund sentiment, aimed at individual investors and small hedge funds.

[object Object]
Preview
9.5
11-14PRnewswire
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

  • Clinical Trials Update: TuHURA Biosciences is conducting a Phase 3 trial of IFx-2.0 as an adjunctive therapy to Keytruda for advanced Merkel cell carcinoma, aiming for accelerated approval from the FDA without a post-approval trial.

  • ASH 2025 Presentations: The company has been selected to present its Delta Opioid Receptor (DOR) technology at the 67th Annual ASH Meeting, highlighting its potential to overcome resistance to cancer immunotherapies.

  • Corporate Developments: Dr. Michael Turner has been appointed as Vice President of Immunology, bringing over 20 years of experience in the field, while TuHURA has filed for a $50 million At-The-Market facility to support its operations.

  • Financial Overview: TuHURA reported $4.9 million in research and development expenses for Q3 2025, with significant net cash outflows, and plans to submit a Phase 2 protocol for TBS-2025 targeting NPM1 mutated AML by the end of 2025.

[object Object]
Preview
9.0
11-03PRnewswire
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

  • DOR Expression in MDSCs and TAMs: Research presented by TuHURA Biosciences reveals that the Delta Opioid Receptor (DOR) is expressed on tumor-associated myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), indicating a novel target for overcoming immunosuppression in cancer therapy.

  • Impact of DOR Inhibition: Inhibition of DOR has been shown to reprogram the immunosuppressive mechanisms of MDSCs and TAMs, potentially enhancing the effectiveness of cancer immunotherapies and addressing acquired resistance.

  • Upcoming Presentations at ASH: TuHURA will present findings at the 67th American Society of Hematology Annual Meeting, including an oral presentation on DOR's role in MDSCs and a poster on its effects on TAMs, highlighting the therapeutic potential of DOR antagonism.

  • TuHURA's Development Pipeline: The company is advancing its immuno-oncology technologies, including a Phase 3 trial for its lead product, IFx-2.0, and plans to develop bi-specific antibody drug conjugates targeting MDSCs to mitigate their immune-suppressing effects.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is TuHURA Biosciences Inc (HURA) stock price today?

The current price of HURA is 1.98 USD — it has increased 3.66 % in the last trading day.

arrow icon

What is TuHURA Biosciences Inc (HURA)'s business?

TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

arrow icon

What is the price predicton of HURA Stock?

Wall Street analysts forecast HURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HURA is 10.00 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is TuHURA Biosciences Inc (HURA)'s revenue for the last quarter?

TuHURA Biosciences Inc revenue for the last quarter amounts to -6.59M USD, increased 216.13 % YoY.

arrow icon

What is TuHURA Biosciences Inc (HURA)'s earnings per share (EPS) for the last quarter?

TuHURA Biosciences Inc. EPS for the last quarter amounts to -11086544.00 USD, increased 382.02 % YoY.

arrow icon

What changes have occurred in the market's expectations for TuHURA Biosciences Inc (HURA)'s fundamentals?

The market is revising No Change the revenue expectations for TuHURA Biosciences, Inc. (HURA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -22.35%.
arrow icon

How many employees does TuHURA Biosciences Inc (HURA). have?

TuHURA Biosciences Inc (HURA) has 1 emplpoyees as of December 05 2025.

arrow icon

What is TuHURA Biosciences Inc (HURA) market cap?

Today HURA has the market capitalization of 101.49M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free